ACTG 260: a Randomized, Phase I-II, Dose-Ranging Trial of the Anti-Human Immunodeficiency Virus Activity of Delavirdine Monotherapy

ACTG 260 was an open-label, four-arm trial designed to study the safety and anti-human immunodeficiency virus (anti-HIV) activity of delavirdine monotherapy at three ranges of concentrations in plasma compared to those of control therapy with zidovudine or didanosine. Delavirdine doses were adjusted...

ver descrição completa

Detalhes bibliográficos

Publicado no:	Antimicrob Agents Chemother
Principais autores:	Para, Michael F., Meehan, Patricia, Holden-Wiltse, Jeanne, Fischl, Margaret, Morse, Gene, Shafer, Robert, Demeter, Lisa M., Wood, Kenneth, Nevin, Tom, Virani-Ketter, Nzeera, Freimuth, William W.
Formato:	Artigo
Idioma:	Inglês
Publicado em:	American Society for Microbiology (ASM) 1999
Assuntos:	Antiviral Agents
Acesso em linha:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC89281/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/10348755/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.43.6.1373
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!